Niche market Cyclopharm is a small, ASX-listed medical device company focused on nuclear medicine and lung imaging with Technegas, presenting an opportunity to expand through partnerships with hospitals and diagnostic imaging centers that rely on ventilation imaging and COPD/PE management.

Expansion potential Given Technegas's established use for pulmonary embolism and emerging indications in COPD, asthma, and related conditions, there is room to upsell additional imaging protocols, SPECT/CT workflows, and training services to imaging departments expanding their ventilation imaging capabilities.

Revenue uplift With current revenue under $1M and a lean team, strategic collaborations with larger distributors or OEM-like partnerships could accelerate market reach for Technegas PAS consumables and the Ultralute radiopharmaceutical production enhancement technology.

Competitive positioning As a specialized player in nuclear medicine imaging, Cyclopharm can differentiate by offering integrated solutions (technique, consumables, and potential production efficiency improvements) to mid-to-large imaging centers seeking cost-effective, high-quality ventilation imaging.

Strategic partnerships Opportunity to engage with global radiopharmacy networks and hospital procurement teams, leveraging Cyclopharm’s niche expertise to cross-sell related imaging agents, training programs, and potential service/support bundles around Technegas and future products.